, Une étude Canadienne s'est intéressée à l'induction intraveineuse mais chez seulement un sous-groupe de 19 patients sur les 167 que comportait leur cohorte, avec un taux de réponse clinique à 3 mois de 57

W. Enfin, 20) ont démontré un bénéfice clinique à 3 mois (défini par l'amélioration des signes cliniques et des tests biologiques) de 65% chez des patients tous en échec d'au moins un anti-TNF et présentant une atteinte luminale de la maladie. De plus, la présence d'un traitement immunosuppresseur à l'induction était significativement reliée au bénéfice clinique à 3 mois (OR 5,43

, Dans notre étude, les cinq patients sous immunosuppresseurs étaient en réponse clinique à la semaine 8 (soit 100% de réponse dans ce sous-groupe) mais aucun lien statistiquement significatif n'a pu être mis en évidence par manque de puissance. Pourtant, dans l'étude randomisée de phase III IM-UNITI(11), peu de patients présentaient des anticorps anti-ustekinumab à 44 semaines de traitement (2,3%) faisant discuter du réel

N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris et al.,

, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology. janv, vol.142, issue.1, pp.46-54, 2012.

G. G. Kaplan, The global burden of IBD: from 2015 to 2025, Nat Rev Gastroenterol Hepatol. déc, vol.12, issue.12, pp.720-727, 2015.

G. G. Kaplan and S. C. Ng, Understanding and Preventing the Global Increase of

, Inflammatory Bowel Disease. Gastroenterology. févr, vol.152, issue.2, pp.313-321, 2017.

L. Pouillon and P. Bossuyt, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease, Expert Opin Biol Ther, vol.16, issue.10, pp.1277-90, 2016.

L. Peyrin-biroulet, W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman et al.,

. Rv, Selecting Therapeutic Targets in Inflammatory Bowel Disease

, Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol. sept, vol.110, issue.9, pp.1324-1362, 2015.

H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos et al.,

, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut. avr, vol.58, issue.4, pp.501-509, 2009.

J. Colombel, W. J. Sandborn, R. Panaccione, A. M. Robinson, W. Lau et al.,

, Adalimumab safety in global clinical trials of patients with Crohn's disease, Inflamm Bowel Dis. sept, vol.15, issue.9, pp.1308-1327, 2009.

B. Christensen, R. J. Colman, D. Micic, P. R. Gibson, S. R. Goeppinger et al.,

, Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety, Inflamm Bowel Dis. 19 mars, vol.24, issue.4, pp.849-60, 2018.

B. E. Sands, B. G. Feagan, P. Rutgeerts, J. Colombel, W. J. Sandborn et al.,

, Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology. sept, vol.147, issue.3, pp.618-627, 2014.

J. M. Benson, D. Peritt, B. J. Scallon, G. A. Heavner, D. J. Shealy et al., Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders, mAbs. déc, vol.3, issue.6, pp.535-580, 2011.

B. G. Feagan, W. J. Sandborn, C. Gasink, D. Jacobstein, Y. Lang et al., Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, N Engl J Med, vol.17, issue.20, pp.1946-60, 2016.

, Recommandation temporaire d'utilisation STELARA, HAS, 2015.

D. Sur, Avis de la Commission de la Transparence sur l'ustekinumab

M. S. Silverberg, J. Satsangi, T. Ahmad, I. Arnott, C. N. Bernstein et al.,

, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol J Can Gastroenterol. sept, vol.19, 2005.

R. F. Harvey and J. M. Bradshaw, A simple index of Crohn's-disease activity, Lancet Lond Engl. 8 mars, vol.1, issue.8167, p.514, 1980.

W. J. Sandborn, C. Gasink, L. Gao, M. A. Blank, J. Johanns et al.,

, Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N Engl J Med, vol.367, issue.16, pp.1519-1547, 2012.

U. Kopylov, W. Afif, A. Cohen, A. Bitton, G. Wild et al., Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience, J Crohns Colitis, vol.8, issue.11, pp.1516-1538, 2014.

S. Khorrami, D. Ginard, I. Marín-jiménez, M. Chaparro, M. Sierra et al.,

, Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort, Inflamm Bowel Dis, vol.22, issue.7, pp.1662-1671, 2016.

C. Ma, R. N. Fedorak, G. G. Kaplan, L. A. Dieleman, S. M. Devlin et al., endoscopic and radiographic outcomes with ustekinumab in medically-refractory

, Crohn's disease: real world experience from a multicentre cohort, Aliment Pharmacol Ther, vol.45, issue.9, pp.1232-1275, 2017.

P. Wils, Y. Bouhnik, P. Michetti, B. Flourie, H. Brixi et al., Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's
URL : https://hal.archives-ouvertes.fr/hal-01214012

, Disease Refractory to Anti-Tumor Necrosis Factor Agents, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. févr, vol.14, issue.2, pp.242-250, 2016.

K. A. Papp, C. Griffiths, K. Gordon, M. Lebwohl, P. O. Szapary et al.,

, Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up, Br J Dermatol. avr, vol.168, issue.4, pp.844-54, 2013.

D. Fiorentino, V. Ho, M. G. Lebwohl, L. Leite, L. Hopkins et al., Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry, J Am Acad Dermatol, vol.77, issue.5, pp.845-854, 2017.